SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharmaceuticals trades higher on the bourses

22 Jan 2013 Evaluate

Sun Pharmaceuticals is currently trading at Rs. 713.50, up by 13.85 points or 1.98% from its previous closing of Rs. 699.65 on the BSE.

The scrip opened at Rs. 700.00 and has touched a high and low of Rs. 715.75 and Rs. 700.00 respectively. So far 24,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 775.90 on 20-Dec-2012 and a 52 week low of Rs. 512.50 on 24-Jan-2012.

Last one week high and low of the scrip stood at Rs. 739.95 and Rs. 694.20 respectively. The current market cap of the company is Rs. 73,886 crore.

The promoters holding in the company stood at 63.68% while Institutions and Non-Institutions held 25.90% and 10.42% respectively.

Sun Pharmaceutical Industries’ subsidiary - Caraco Pharmaceutical Laboratories has completed tender offer to acquire Dusa Pharmaceuticals for $8.00 per share, net to the seller thereof in cash, without interest thereon and less any applicable withholding taxes. As per the company, after the tender offer's expiration, 2,09,46,624 shares of common stock of Dusa had been validly tendered, representing nearly 82.4% of the outstanding shares of Dusa.

Caraco Pharmaceutical will move forward with a “short-form” merger under New Jersey law after exercising its top-up option under the merger agreement, and DUSA will become a wholly owned subsidiary of the company. Following the merger, DUSA's shares will cease to be traded on The NASDAQ Global Market.

Sun Pharma Inds. Share Price

1862.60 -9.80 (-0.52%)
12-May-2026 12:29 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1862.60
Dr. Reddys Lab 1279.30
Cipla 1298.60
Zydus Lifesciences 939.45
Lupin 2267.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×